Insulin Dependent Diabetes Mellitus, Type 2 Diabetes Mellitus 2
Conditions
Keywords
Type 2 Diabetes Mellitus, insulin, fear, pain,, curtain, Self-Injection
Brief summary
Diabetes is a global problem for the world and negatively affects life (1). The most important reasons for ineffective diabetes and insulin treatment include fear of insulin side effects, fear of insulin injection, social embarrassment from administering insulin, fear of hypoglycemia and/or hyperglycemia (2). A large portion of diabetic individuals experience these fears, and some of these patients cope with these fears and integrate them into their daily lifestyles. However, some diabetic patients may be ineffective in coping with these fears (3). This situation creates negativities in the individual's success in treatment and compliance with treatment (3). Diverting attention is one of the non-pharmacological methods used in pain control. Diverting attention is one of the most preferred methods in reducing the pain experienced by patients during diagnosis and treatment procedures. It is a method that allows patients to control and reduce their symptoms by focusing their attention on a different point (4). In this study, the use of a distracting curtain during self-injection in individuals with Type 2 diabetes will be examined in order to examine the effect of pain and fear.
Detailed description
Research Type: It is designed as a randomized controlled, regular research. Research Universe and Samples: The research groups will be the living diabetes cells of Dicle University Hospitals. The research aims to create 100 healthy diabetes patients in Dicle University Hospital.
Interventions
OTHERShowing a nature view curtain to type 2 diabetic patients during insulin injection
a nature view curtain
Sponsors
Dicle University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
They do not know the experimental or control procedures that take place
Intervention model description
study group and control group
Eligibility
Sex/Gender
ALL
Age
15 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes for at least one year * self-administering insulin injections * self-administering a glucometer, insulin pen or insulin pump,
Exclusion criteria
* poor mental health * Having gestational diabetes mellitus or Type 1 Diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Scale -VAS | Before insulin administration on day one Time Frame: After two insulin administration on the second day | The VAS scale is used to assess subjectively perceived pain. The VAS scale is a 10 cm (100 mm) ruler with no pain at one end and the most severe pain at the other end. The individuals participating in the study were asked to mark the intensity of the pain they felt at that moment by explaining that the number 0 on the scale means I do not feel any pain and that the pain intensity increases as the numbers increase and that the number 10 means I feel the most severe pain. In the evaluation, an increase in the score obtained from the scale indicates an increase in pain. It will be administered before and after each insulin injection. Each patient will be administered three times. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diabetes Fear of Self Injecting and Self-testing Questionnaire-D-FISQ | Before insulin administration on day one Time Frame: After two insulin administration on the second day | The D-FISQ consists of two subscales: fear of self-injection (fear of self-injecting-FSI, 6 statements) and fear of self-testing (fear of self-testingFST, 9 statements). Each statement has a four-point Likert-type scale ranging from 0 to 3 (0= almost never, 1= sometimes, 2= often, 3= almost always). The evaluation of the questionnaire can be done by taking the average or raw score for the two sub-dimensions and the whole questionnaire. When taken as raw score, self-injection fear score ranges between 0-18, self-testing fear score ranges between 0-27, and total fear score ranges between 0-45. An increase in score indicates an increase in fear. It will be administered before and after each insulin injection. Each patient will be administered three times. |
Countries
Turkey (Türkiye)
Outcome results
None listed